← Human Trials & Peer-Reviewed Studies
User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
Plain-language guide to PMID 33407242 (2021): observational study of Angiotensin II in 121 patients.
Key Facts
- PMID
- 33407242
- Journal
- BMC nephrology
- Year
- 2021
- Study type
- Observational Study
- Authors
- Takaori K et al. (4 authors)
- DOI
- 10.1186/s12882-020-02198-6
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II, published as an observational study.
Vascular calcification is a prominent feature in chronic kidney disease (CKD) and diabetes mellitus.
Therefore, the researchers investigated the relationship between vascular calcification and use of angiotensin-converting-enzyme inhibitor (ACEI) and/or angiotensin II receptor blocker (ARB) from a cross-sectional view.
Who Took Part
The abstract describes 121 patients taking part.
PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.
A total of 121 predialysis CKD patients (age 71 ± 12 y; male 72; estimated glomerular filtration rate (eGFR) 20.2 (11.8 - 40.3) mL/min/1.73 m2) who underwent thoracoabdominal plain computed tomography scan were included in this study.
The total vascular calcification volume (Calc) was calculated with a three-dimensional imaging software and standardized by body surface area (BSA).
How the Study Was Run
The relevance between log [Calc/BSA] and ACEI/ARB use was investigated by multivariate linear regression analyses with or without a time-duration factor of ACEI/ARB use.
What Was Measured
Topics PubMed links to this paper include Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Cross-Sectional Studies, Renal Insufficiency, Chronic and Vascular Calcification.
Author keywords: ACE inhibitor, ARB and Angiotensin II.
What This Means in Plain Language
This is an observational study of Angiotensin II in 121 patients.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2021 (BMC nephrology), a journal based in England.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.